Addendum¹ to
"The use of stems in the selection of International Nonproprietary names (INN) for pharmaceutical substances"
WHO/EMP/RHT/TSN/2018.1

Programme on International Nonproprietary Names (INN)

Health Products Policy and Standards

World Health Organization, Geneva

¹© World Health Organization 2019 - All rights reserved. The contents of this document may not be reviewed, abstracted, quoted, referenced, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means, without explicit prior authorization of the WHO INN Programme.

This document contains the collective views of the INN Expert Group and does not necessarily represent the decisions or the stated policy of the World Health Organization.
Addendum¹ to "The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances" - WHO/EMP/RHT/TSN/2018.1

¹ This addendum is a cumulative list of all new stems selected by the INN Expert Group since the publication of "The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances" 2018.

- **caftor**
  cystic fibrosis transmembrane regulator (CFTR) protein modulators, correctors, and amplifiers
  bamocaftor (121), deutivacaftor (118), elexacaftor (121), galicaftor (119), ivacaftor (104), lumacaftor (105), navocaftor (121), olacaftor (119), tezacaftor (114)

- **calcet/-calcet**
  calcium-sensing receptors (CaSR) agonists
  cinacalcet (88), etelcalcetide (112), evocalcet (113), tecalcet (87), upacicalcet (118)

- **copan**
  complement receptor antagonists/ complement inhibitors
  avacopan (114), danicopan (119), nomacopan (119)
  (c)category: pegcetacoplan (120), zilucoplan (118)

- **fexor**
  farnesoid X receptor agonists
  cilofexor (119), nidufexor (118), tropifexor (116), turofexorate isopropyl (103)

- **fusp**
  fusion proteins¹
  bintrafusp alfa (121), cinrebufusp alfa (121), clervonafusp alfa (120), lorukafusp alfa (120), onfekafusp alfa (118), pabinafusp alfa (120), rozibafusp alfa (120), simlukafusp alfa (121), tagraxofusp (118), tebentafusp (118), valanafusp alfa (118)

- **golix**
  gonadotropin releasing hormone (GnRH) antagonists
  elagolix (99), linzagolix (118), opigolix (118), relugolix (107), sufugolix (89)

¹ A fusion protein is defined as a multifunctional protein derived from a single nucleotide sequence which may contain two or more genes or portions of genes with or without amino acid linker sequences. The genes should originally code for separate proteins, with at least two of them endowed with pharmacological action (e.g. action and targeting). “Notes from the fusion protein Working Group”, INN Working Document number 17.414 rev.
<table>
<thead>
<tr>
<th>Stem</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>-ixibat</td>
<td>ileal bile acid transporter (IBAT) inhibitors, bile acid reabsorption inhibitors</td>
</tr>
<tr>
<td></td>
<td>barixibat (88), elobixibat (104), linerixibat (118), maralixibat chloride (113), odevixibat (119), volixibat (113)</td>
</tr>
<tr>
<td>-leuton</td>
<td>5-lipo-oxygenase inhibitors, anti-inflammatory</td>
</tr>
<tr>
<td></td>
<td>atreleuton (78), diroleuton (118), epeleuton (118), fenleuton (72), setileuton (101), zileuton (63)</td>
</tr>
<tr>
<td>stat</td>
<td>enzyme inhibitors</td>
</tr>
<tr>
<td>-glustat</td>
<td>ceramide glucosyltransferase inhibitors</td>
</tr>
<tr>
<td></td>
<td>duvoglustat (102), eliglustat (103), miglustat (85), sinbaglustat (121), venglustat (114)</td>
</tr>
<tr>
<td>-tinib</td>
<td>tyrosine kinase inhibitors</td>
</tr>
<tr>
<td>-ertinib</td>
<td>epidermal growth factor receptor (EGFR) inhibitors</td>
</tr>
<tr>
<td></td>
<td>abivertinib (119), osimertinib (113), epertinib (115), canertinib (87), lazertinib (117), mavelertinib (118), mobocertinib (121), olafertinib (121), xiliertinib (121), zorifertinib (121)</td>
</tr>
<tr>
<td>(b) category:</td>
<td>ulixertinib (113), ravoxertinib (115) (Erk inhibitors)</td>
</tr>
<tr>
<td>(c) category:</td>
<td>afatinib (104), olmutinib (114), erlotinib (85), gefitinib (85), mubritinib (90), nazartinib (114), mubritinib (90), nazartinib (114)</td>
</tr>
<tr>
<td>-tirom(-)</td>
<td>antihyperlidaemic; thyromimetic derivatives</td>
</tr>
<tr>
<td></td>
<td>acetiromate (30), axitirome (82), bentiromide (41), eprotirome (99), resmetirom (119), sobetirome (100)</td>
</tr>
<tr>
<td>-toclax</td>
<td>B-cell lymphoma 2 (Bcl-2) inhibitors, antineoplastics</td>
</tr>
<tr>
<td></td>
<td>obatoclax (94), navitoclax (103), venetoclax (111), imlatoclax (115), tapotoclax (121), mirzotamab clezutoclax (121)</td>
</tr>
</tbody>
</table>
The following stems definitions have also been amended as below:

**-imus**
from **immunosuppressants, other than antineoplastics**
to
**immunosuppressants, other than antineoplastics**

**-isant**
from **histamine H₃ receptor antagonists**
to
**histamine H₃ receptor antagonists, inverse agonists**

under **-tant**

**-netant**
from **neurokinin NK3 receptor antagonists**
to
**neurokinin NK3 and dual NK3-NK1 receptor antagonists**

**-pressin**
from **vasoconstrictors, vasopressin derivatives**
to
**vasoconstrictors, vasopressin analogues**